Sign In
Buy EDIT
$2.78
-0.0400 (-1.42%)
At Close: Jun 03, 2026
Sherlock, binx to develop point-of-care Covid-19 test using CRISPR technology
05:54pm, Wednesday, 01'st Jul 2020
The Food and Drug Administration had previously granted an emergency use authorization for Abbott's ID NOW point-of-care test, a decision for which the agency came under fire amid reports of the test
Analyzing Avrobio (NASDAQ:AVRO) & Editas Medicine (NASDAQ:EDIT)
02:54am, Tuesday, 30'th Jun 2020
Avrobio (NASDAQ:AVRO) and Editas Medicine (NASDAQ:EDIT) are both small-cap medical companies, but which is the superior business? We will contrast the two businesses based on the strength of their ins
CRISPR Therapeutics Is a Top Pick for Piper Sandler. Here’s Why.
02:50pm, Monday, 29'th Jun 2020
CRISPR Therapeutics announced last Thursday that it would build a new manufacturing facility in Massachusetts to produce its experimental cell therapies....
Cellectis Starting To Look Like A Biotech Buy
01:35pm, Monday, 29'th Jun 2020
Cellectis has shown promise in its oncology treatment and a new paper shows that it's able to overcome early risk detection. A new chief medical officer signing
Do Hedge Funds Love Editas Medicine, Inc. (EDIT)?
02:20am, Sunday, 28'th Jun 2020
At the end of February we announced the arrival of the first US recession since 2009 and we predicted that the market will decline by at least 20% in (Recession is Imminent: We Need A Travel Ban NOW).
Editas Medicine, Inc. (EDIT), a leading genome editing company, today announced the closing of its previously announced underwritten offering of 6,900,000 shares of its common stock at a public offeri
How gene therapy and CRISPR are helping to cure blindness
12:21pm, Friday, 26'th Jun 2020
In recent months, even as our attention has been focused on the coronavirus outbreak, there have been a slew of scientific breakthroughs in treating diseases that cause blindness. Researchers at U.S.
How Crispr Therapeutics Can Change Everything
12:20pm, Friday, 26'th Jun 2020
But if you want to profit from CRISPR stock, you better get in before the potential pop.
The Incredible Gene-Therapy Breakthroughs to Cure Blindness
08:34am, Friday, 26'th Jun 2020
Some involved the gene-editing technique known as CRISPR. One involves putting a specially engineered gold particle into the retina.
Nuveen Asset Management LLC Purchases 73,787 Shares of Editas Medicine Inc (NASDAQ:EDIT)
06:06am, Friday, 26'th Jun 2020
Nuveen Asset Management LLC raised its stake in shares of Editas Medicine Inc (NASDAQ:EDIT) by 28.9% during the 1st quarter, Holdings Channel reports. The fund owned 328,752 shares of the company’s
How gene therapy and CRISPR are helping to cure blindness
06:11pm, Thursday, 25'th Jun 2020
The eye is an ideal organ for testing new therapeutic approaches, including CRISPR.
Editas Medicine Falling 6% In Pre-Market On Offer Pricing
09:12am, Wednesday, 24'th Jun 2020
Shares in Editas Medicine (EDIT) are falling 6% in Wednesday’s pre-market trading after the company announced a price of $31.25 per share for its
Editas Medicine Announces Pricing of Offering of Common Stock
01:48am, Wednesday, 24'th Jun 2020
Editas Medicine, Inc. (EDIT), a leading genome editing company, today announced the pricing of an underwritten offering of 6,000,000 shares of its common stock at a public offering price of $31.25 per
Editas Medicine Announces Pricing of Offering of Common Stock
12:00am, Wednesday, 24'th Jun 2020
CAMBRIDGE, Mass., June 23, 2020 (GLOBE NEWSWIRE) -- Editas Medicine, Inc. (Nasdaq: EDIT), a leading genome editing company, today announced the pricing...
First sickle cell patient to use CRISPR says technology is working
09:53pm, Tuesday, 23'rd Jun 2020
Mother-of-four Victoria Gray, 34, of Forest, Mississippi, says the controversial gene-editing tool CRISPR has helped alleviate her of severe bouts of pain due to sickle cell disease.
